Investigating the cardio-protective abilities of supplemental l-arginine on parameters of endothelial function in a hypercholesterolemic animal model

Journal of Nutritional Science and Vitaminology

Volumn 60, Issue 3, 2014, Pages 145-151

  Gad, Mohamed Z ^a   Abu El Maaty, Mohamed A ^a   El Maraghy, Shohda A ^b   Fahim, Atef T ^b   Hamdy, Mohamed A ^b  

^a German University in Cairo   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Cardio protection; Endothelial function; L arginine

Indexed keywords

AMIDASE; ARGININE; CARDIOTONIC AGENT; DIMETHYLARGININASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLYCERYL TRINITRATE; MALONALDEHYDE; NITRIC OXIDE;

ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; DIET SUPPLEMENTATION; DISEASE MODEL; DRUG EFFECTS; HEART; HYPERCHOLESTEROLEMIA; MALE; METABOLISM; OXIDATIVE STRESS; RABBIT; VASCULAR ENDOTHELIUM;

AMIDOHYDROLASES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ARGININE; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; ENALAPRIL; ENDOTHELIUM, VASCULAR; HEART; HYPERCHOLESTEROLEMIA; MALE; MALONDIALDEHYDE; NITRIC OXIDE; NITROGLYCERIN; OXIDATIVE STRESS; RABBITS;

EID: 84905188137     PISSN: 03014800     EISSN: 18817742     Source Type: Journal    
DOI: 10.3177/jnsv.60.145     Document Type: Article

References (33)

1. Potente M, Dimmeler S. 2008. NO targets SIRT1: a novel signaling network in endothelial senescence. Arterioscler Thromb Vasc Biol 28: 1577-1579.
2. Endemann DH, Schiffrin EL. 2004. Endothelial dysfunction. J Am Soc Nephrol 15: 1983-1992.
3. Gad MZ. 2010. Anti-aging effects of L-arginine. J Adv Res 1: 169-177.
4. Dioguardi FS. 2011. To give or not to give? Lessons from the arginine paradox. J Nutrigenet Nutrigenomics 4: 90-98.
5. Boger RH. 2004. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr 134: 2842S-2847S; discussion 2853S.
6. El-Mesallamy HO, Abdel Hamid SG, Gad MZ. 2008. Oxidative stress and asymmetric dimethylarginine are associated with cardiovascular complications in hemodialysis patients: improvements by L-arginine intake. Kidney Blood Press Res 31: 189-195.
7. Khalifa NM, Gad MZ, Hataba AA, Mahran LG. 2012. Changes in ADMA and TAFI levels after stenting in coronary artery disease patients. Mol Med Report 6: 855-859.
8. Gad MZ, Hassanein SI, Abdel-Maksoud SM, Shaban GM, Abou-Aisha K, Elgabarty HA. 2010. Assessment of serum levels of asymmetric dimethylarginine, symmetric dimethylarginine and L-arginine in coronary artery disease. Biomarkers 15: 746-752.
9. Yan C, Kim D, Aizawa T, Berk BC. 2003. Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator. Arterioscler Thromb Vasc Biol 23: 26-36.
10. Ackermann A, Fernandez-Alfonso MS, Sanchez de Rojas R, Ortega T, Paul M, Gonzalez C. 1998. Modulation of angiotensin-converting enzyme by nitric oxide. Br J Pharmacol 124: 291-298.
11. Higashi Y, Oshima T, Ono N, Hiraga H, Yoshimura M, Watanabe M, Matsuura H, Kambe M, Kajiyama G. 1995. Intravenous administration of L-arginine inhibits angiotensin-converting enzyme in humans. J Clin Endocrinol Metab 80: 2198-2202.
12. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, Takeshita A. 1997. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by longterm blockade of nitric oxide synthesis in rats. J Clin Invest 99: 278-287.
13. Gokkusu C, Oz H. 1991. Effect of thymosin fraction 5 (F5) on erythrocyte glutathione and lipid peroxide levels in hypercholesterolemic rabbits. Int J Vitam Nutr Res 61: 87-90.
14. Tsao PS, Theilmeier G, Singer AH, Leung LL, Cooke JP. 1994. L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscler Thromb 14: 1529-1533.
15. Hoshida S, Nishida M, Yamashita N, Igarashi J, Aoki K, Hori M, Kuzuya T, Tada M. 1997. Vascular angiotensinconverting enzyme activity in cholesterol-fed rabbits: effects of enalapril. Atherosclerosis 130: 53-59.
16. Bryan NS, Grisham MB. 2007. Methods to detect nitric oxide and its metabolites in biological samples. Free Radic Biol Med 43: 645-657.
17. Holmquist B, Bunning P, Riordan JF. 1979. A continuous spectrophotometric assay for angiotensin converting enzyme. Anal Biochem 95: 540-548.
18. Knipp M, Vasak M. 2000. A colorimetric 96-well microtiter plate assay for the determination of enzymatically formed citrulline. Anal Biochem 286: 257-264.
19. Mihara M, Uchiyama M. 1978. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 86: 271-278.
20. Born GV. 1962. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194: 927-929.
21. Prasad K. 1999. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 99: 1355-1362.
22. Chen Y, Zhou M, Kong H. 1993. Lipoperoxidative damage in experimental rabbits with atherosclerosis. Chin Med J (Engl) 106: 110-114.
23. Bode-Boger SM, Boger RH, Kienke S, Junker W, Frolich JC. 1996. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 219: 598-603.
24. Boger RH, Bode-Boger SM, Mugge A, Kienke S, Brandes R, Dwenger A, Frolich JC. 1995. Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis 117: 273-284.
25. de la Pena NC, Sosa-Melgarejo JA, Ramos RR, Mendez JD. 2000. Inhibition of platelet aggregation by putrescine, spermidine, and spermine in hypercholesterolemic rabbits. Arch Med Res 31: 546-550.
26. Hoshida S, Yamashita N, Kawahara K, Kuzuya T, Hori M. 1999. Amelioration by quinapril of myocardial infarction induced by coronary occlusion/reperfusion in a rabbit model of atherosclerosis: possible mechanisms. Circulation 99: 434-440.
27. Candipan RC, Wang BY, Buitrago R, Tsao PS, Cooke JP. 1996. Regression or progression. Dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol 16: 44-50.
28. Ichiki T, Usui M, Kato M, Funakoshi Y, Ito K, Egashira K, Takeshita A. 1998. Downregulation of angiotensin II type 1 receptor gene transcription by nitric oxide. Hypertension 31: 342-348.
29. Saleh AI, Abdel Maksoud SM, El-Maraghy SA, Gad MZ. 2011. Protective effect of L-arginine in experimentally induced myocardial ischemia: comparison with aspirin. J Cardiovasc Pharmacol Ther 16: 53-62.
30. Boger RH, Bode-Boger SM, Phivthong-ngam L, Brandes RP, Schwedhelm E, Mugge A, Bohme M, Tsikas D, Frolich JC. 1998. Dietary L-arginine and alpha-tocopherol reduce vascular oxidative stress and preserve endothelial function in hypercholesterolemic rabbits via different mechanisms. Atherosclerosis 141: 31-43.
31. Moritoki H, Takeuchi S, Hisayama T, Kondoh W. 1992. Nitric oxide synthase responsible for L-arginine-induced relaxation of rat aortic rings in vitro may be an inducible type. Br J Pharmacol 107: 361-366.
32. Berlin E, Shapiro SG, Friedland M. 1984. Platelet membrane fluidity and aggregation of rabbit platelets. Atherosclerosis 51: 223-239.
33. Cannon RO 3rd. 1998. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem 44: 1809-1819.